Search

Your search keyword '"Hutson, Thomas E."' showing total 648 results
Start Over Author "Hutson, Thomas E."
648 results on '"Hutson, Thomas E."'

3. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Tomczak, Piotr, Choueiri, Toni, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas R., Hajek, Jaroslav, Lin, Tzu-Ping, Symeonides, Stefan N., Lee, Jae Lyun, Sawrycki, Piotr, Haas, Naomi B., Gurney, Howard P., Mahave, Mauricio, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Chevreau, Christine, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Topart, Delphine, Oudard, Stephane, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Quinn, David I., Alva, Ajjai, Menezes, Juliana de Janoski, Silva, Adriano Goncalves e, Winquist, Eric W., Hamzaj, Alketa, Procopio, Giuseppe, Karaszewska, Boguslawa, Nowakowska-Zajdel, Ewa M., Alekseev, Boris Y., Gafanov, Rustem A., Izmailov, Adel, Semenov, Andrey, Afanasyev, Sergey G., Lipatov, Oleg N., Powles, Thomas B., Srinivas, Sandy, McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Chung, Jinsoo, Shkolnik, Michail I., Matveev, Vsevolod B., Gajate Borau, Pablo, McCune, Steven, Hutson, Thomas E., Dri, Alejandro, Sales, Silvio Correia, Yeung, Carrie, Alcala Castro, Carmen Marcela, Bostrom, Peter, Laguerre, Brigitte, Buttigliero, Consuelo, de Giorgi, Ugo, Fomin, Eugeniy A., Zakharia, Yousef, Hwang, Clara, Singer, Eric A., Yorio, Jeffrey T., Waterhouse, David, Kowalyszyn, Ruben Dario, Alfie, Margarita Sonia, Yanez Ruiz, Eduardo, Buchler, Tomas, Kankaanranta, Krista, Ferretti, Gianluigi, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Tamada, Satoshi, Kato, Haruaki, Kitamura, Hiroshi, Danielewicz, Iwona, Wojcik-Tomaszewska, Joanna, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Rojas-Uribe, Gustavo Adolfo, Gonzalez Fernandez, Manuel Enrique, Feyerabend, Susan, Pignata, Sandro, Numakura, Kazuyuki, Cybulska Stopa, Bozena, Zukov, Ruslan, Climent Duran, Miguel Angel, Maroto Rey, Pablo Jose, Montesa Pino, Alvaro, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Cobb, Patrick W., Hauke, Ralph, Anderson, Daniel M., Sarantopoulos, John, Gourdin, Theodore, Zhang, Tian, Jayram, Gautam, Fein, Luis Enrique, Harris, Carole, Beato, Patricia Medeiros Milhomem, Flores, Francisco, Estay, Angela, Rubiano, Juan Andres, Bedke, Jens, Hauser, Stefan, Neisius, Andreas, Busch, Jonas, Anai, Satoshi, Tsunemori, Hiroyuki, Sawka, Dariusz, Sikora-Kupis, Bozena, Arranz, Jose Angel, Delgado, Ignacio, Chen, Chung-Hsin, Gunderson, Elizabeth, Tykodi, Scott, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Kaen, Diego Lucas, Sade, Juan Pablo, Tatangelo, Marcelo Daniel, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Marceau, Daniele, Paradis, Jean-Benoit, Hanna, Nawar, Acevedo, Alejandro, Ibanez, Carolina, Villanueva, Luis, Galaz, Pedro Pablo, Durango, Isabel Cristina, Manneh, Ray, Kral, Zdenek, Holeckova, Petra, Hakkarainen, Heikki, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Tartas, Sophie, Goebell, Peter J., Grimm, Marc-Oliver, Hoefner, Thomas, Wirth, Manfred, Panic, Andrej, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Mizuno, Ryuichi, Uemura, Hirotsugu, Eto, Masatoshi, Tsujihata, Masao, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Hamberg, Paul, Marczewska-Skrodzka, Malgorzata, Szczylik, Cezary, Humphreys, Alison C., Jiang, Peter, Kumar, Birendra, Lu, Gary, Desai, Arpita, Karam, Jose Antonio, Keogh, George, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Mendez, Guillermo Ariel, Harris, Samuel J., Brown, Stephen J., Antonio Junior, Joao Neif, Costamilan, Rita de Cassia, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Lalani, Aly-Khan, Graham, Jeffrey, Levesque, Michael, Orlandi, Francisco, Kotasek, Rostislav, Deville, Jean L., Borchiellini, Delphine, Merseburger, Axel, Rink, Michael, Roos, Frederik, McDermott, Ray, Oyama, Masafumi, Yamamoto, Yoshiaki, Tomita, Yoshihiko, Miura, Yuji, Ioritani, Naomasa, Westgeest, Hans, Kubiatowski, Tomasz, Bal, Wieslaw, Girones Sarrio, Regina, Rowe, Julie, Prow, Debra M., Senecal, Francis, Hashemi-Sadraei, Neda, Cole, Scott W., Kendall, Stephan D., Richards, Donald A., Schnadig, Ian D., Gupta, Mukul, Powles, Thomas, Ferguson, Thomas, Symeonides, Stefan N, Gurney, Howard, Chang, Yen-Hwa, Haas, Naomi B, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Quinn, David I, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

4. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

Author

Costello, Brian A., Bhavsar, Nrupen A., Zakharia, Yousef, Pal, Sumanta K., Vaishampayan, Ulka, Jim, Heather, Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che-Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Mardekian, Jack, Borham, Azah, George, Daniel J., and Harrison, Michael R.

Published
2022
Full Text
View/download PDF

5. Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo.

Author

Qin, Qian, primary, Brugarolas, James, additional, Hammers, Hans J., additional, Arafat, Waddah, additional, Courtney, Kevin Dale, additional, Wang, Jue, additional, Jiang, Changchuan, additional, Zhang, Song, additional, Cowey, Charles Lance, additional, Hutson, Thomas E., additional, and Zhang, Tian, additional

Published
2024
Full Text
View/download PDF

6. A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.

Author

Dudek, Arkadiusz Z., primary, O'Shaughnessy, Joyce, additional, Piha-Paul, Sarina A., additional, Uprety, Dipesh, additional, Kitchens, Benjamin Lee, additional, Hutson, Thomas E., additional, Rank, Brian H., additional, Stokes, Michael, additional, Dudgeon, Crissy, additional, Surguladze, David, additional, Lightcap, Eric, additional, Drees, Jeremy, additional, Harrison, Ben, additional, Li, Richard, additional, LaCayo, Ashley, additional, Mattson, Paulette, additional, Bose, Nandita, additional, Karim, Dhamina, additional, Gargano, Michele Anne, additional, and Iglesias, Jose Luis, additional

Published
2024
Full Text
View/download PDF

7. Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.

Author

Motzer, Robert J., primary, Porta, Camillo, additional, Eto, Masatoshi, additional, Hutson, Thomas E., additional, Rha, Sun Young, additional, Merchan, Jaime R., additional, Winquist, Eric, additional, Gurney, Howard, additional, Grünwald, Viktor, additional, George, Saby, additional, Markensohn, Julia, additional, Burgents, Joseph E., additional, Cristescu, Razvan, additional, Narita, Yudai, additional, He, Cixin S., additional, Zhao, Ziming, additional, Okpara, Chinyere E, additional, Minoshima, Yukinori, additional, and CHOUEIRI, Toni K., additional

Published
2024
Full Text
View/download PDF

11. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

Author

Powles, Thomas, Atkins, Michael B., Escudier, Bernard, Motzer, Robert J., Rini, Brian I., Fong, Lawrence, Joseph, Richard W., Pal, Sumanta K., Sznol, Mario, Hainsworth, John, Stadler, Walter M., Hutson, Thomas E., Ravaud, Alain, Bracarda, Sergio, Suarez, Cristina, Choueiri, Toni K., Reeves, James, Cohn, Allen, Ding, Beiying, Leng, Ning, Hashimoto, Kenji, Huseni, Mahrukh, Schiff, Christina, and McDermott, David F.

Published
2021
Full Text
View/download PDF

12. Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Author

Grünwald, Viktor, primary, Powles, Thomas, additional, Eto, Masatoshi, additional, Kopyltsov, Evgeny, additional, Rha, Sun Young, additional, Porta, Camillo, additional, Motzer, Robert, additional, Hutson, Thomas E., additional, Méndez-Vidal, María José, additional, Hong, Sung-Hoo, additional, Winquist, Eric, additional, Goh, Jeffrey C., additional, Maroto, Pablo, additional, Buchler, Tomas, additional, Takagi, Toshio, additional, Burgents, Joseph E., additional, Perini, Rodolfo, additional, He, Cixin, additional, Okpara, Chinyere E., additional, McKenzie, Jodi, additional, and Choueiri, Toni K., additional

Published
2024
Full Text
View/download PDF

15. Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

Author

Basch, Ethan M., Scholz, Mark, de Bono, Johann S., Vogelzang, Nicholas, de Souza, Paul, Marx, Gavin, Vaishampayan, Ulka, George, Saby, Schwarz, James K., Antonarakis, Emmanuel S., O'Sullivan, Joseph M., Kalebasty, Arash Rezazadeh, Chi, Kim N., Dreicer, Robert, Hutson, Thomas E., Dueck, Amylou C., Bennett, Antonia V., Dayan, Erica, Mangeshkar, Milan, Holland, Jaymes, Weitzman, Aaron L., and Scher, Howard I.

Published
2019
Full Text
View/download PDF

16. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

Author

Beckermann, Kathryn E, primary, Asnis-Alibozek, Aviva G, additional, Atkins, Michael B, additional, Escudier, Bernard, additional, Hutson, Thomas E, additional, Kasturi, Vijay, additional, McDermott, David F, additional, Pal, Sumanta K, additional, Porta, Camillo, additional, Rini, Brian I, additional, and Verzoni, Elena, additional

Published
2024
Full Text
View/download PDF

22. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Author

Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime, Goh, Jeffrey C., Lalani, Aly-Khan A., De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Méndez-Vidal, María José, Kopyltsov, Evgeny, Tjulandin, Sergei, Gordoa, Teresa Alonso, and Kozlov, Vadim

Published
2024
Full Text
View/download PDF

23. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

Author

Grünwald, Viktor, Powles, Thomas, Masatoshi Eto, Kopyltsov, Evgeny, Sun Young Rha, Porta, Camillo, Motzer, Robert, Hutson, Thomas E., José Méndez-Vidal, María, Sung-Hoo Hong, Winquist, Eric, Goh, Jeffrey C., Maroto, Pablo, Buchler, Tomas, Toshio Takagi, Burgents, Joseph E., Perini, Rodolfo, Cixin He, Okpara, Chinyere E., and McKenzie, Jodi

Subjects
SUNITINIB, RENAL cell carcinoma, BONE metastasis, THERAPEUTICS, TREATMENT effectiveness, PROGRESSION-free survival
Abstract

Introduction: The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence and/or site of baseline metastases, prior nephrectomy, and sarcomatoid features have been associated with disease and treatment success. This subsequent analysis explores outcomes in patients with or without specific prognostic features. Methods: In CLEAR, patients with clear cell RCC were randomly assigned (1:1:1) to receive either lenvatinib (20 mg/day) plus pembrolizumab (200 mg every 3 weeks), lenvatinib (18 mg/day) plus everolimus (5 mg/day), or sunitinib alone (50 mg/day, 4 weeks on, 2 weeks off). In this report, progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were all assessed in the lenvatinib-plus-pembrolizumab and the sunitinib arms, based on baseline features: lung metastases, bone metastases, liver metastases, prior nephrectomy, and sarcomatoid histology. Results: In all the assessed subgroups, median PFS was longer with lenvatinib-plus-pembrolizumab than with sunitinib treatment, notably among patients with baseline bone metastases (HR 0.33, 95% CI 0.21–0.52) and patients with sarcomatoid features (HR 0.39, 95% CI 0.18–0.84). Median OS favored lenvatinib plus pembrolizumab over sunitinib irrespective of metastatic lesions at baseline, prior nephrectomy, and sarcomatoid features. Of interest, among patients with baseline bone metastases the HR for survival was 0.50 (95% CI 0.30–0.83) and among patients with sarcomatoid features the HR for survival was 0.91 (95% CI 0.32–2.58); though for many groups, median OS was not reached. ORR also favored lenvatinib plus pembrolizumab over sunitinib across all subgroups; similarly, complete responses also followed this pattern. Conclusion: Efficacy outcomes improved following treatment with lenvatinib-plus-pembrolizumab versus sunitinib in patients with RCC—irrespective of the presence or absence of baseline lung metastases, baseline bone metastases, baseline liver metastases, prior nephrectomy, or sarcomatoid features. These findings corroborate those of the primary CLEAR study analysis in the overall population and support lenvatinib plus pembrolizumab as a standard of care in 1L treatment for patients with advanced RCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.

Author

Grivas, Petros, Barata, Pedro C., Moon, Helen H., Gupta, Shilpa, Hutson, Thomas E., Sternberg, Cora N., Brown, Jason, Dave, Vaidehi, Downey, Chad, Shillington, Alicia C., Katzenstein, Howard, Kirker, Melissa, Hanson, Sarah, Liu, Frank X., Morris, Valerie A., Bhanegaonkar, Abhijeet, and Sonpavde, Guru P.

Published
2024
Full Text
View/download PDF

25. Development of a patient-centered health-related quality of life (HRQOL) measure for metastatic renal cell carcinoma (mRCC): A three-phase study.

Author

Bergerot, Cristiane Decat, Castro, Daniela V., Bergerot, Paulo Gustavo, Mercier, Benjamin D., Nally, Elizabeth, Ali, Adil A., Philip, Errol James, Buso, Murilo, Hutson, Thomas E., Grünwald, Viktor, Bex, Axel, Psutka, Sarah P., Rini, Brian I., Plimack, Elizabeth R., Master, Viraj A., Albiges, Laurence, Choueiri, Toni K., Pal, Sumanta Kumar, and Powles, Thomas

Published
2024
Full Text
View/download PDF

29. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

Author

Bono, Petri, Oudard, Stephane, Bodrogi, Istvan, Hutson, Thomas E., Escudier, Bernard, Machiels, Jean-Pascal, Thompson, John A., Figlin, Robert A., Ravaud, Alain, Basaran, Mert, Porta, Camillo, Bracarda, Sergio, Brechenmacher, Thomas, Lin, Chinjune, Voi, Maurizio, Grunwald, Viktor, and Motzer, Robert J.

Published
2016
Full Text
View/download PDF

30. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Author

Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Tannir, Nizar M, Mainwaring, Paul N, Rini, Brian I, Hammers, Hans J, Donskov, Frede, Roth, Bruce J, Peltola, Katriina, Lee, Jae Lyun, Heng, Daniel Y C, Schmidinger, Manuela, Agarwal, Neeraj, Sternberg, Cora N, McDermott, David F, Aftab, Dana T, Hessel, Colin, Scheffold, Christian, Schwab, Gisela, Hutson, Thomas E, Pal, Sumanta, and Motzer, Robert J

Published
2016
Full Text
View/download PDF

32. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Author

Motzer, Robert J., primary, Hutson, Thomas E., additional, Tomczak, Piotr, additional, Michaelson, M. Dror, additional, Bukowski, Ronald M., additional, Oudard, Stéphane, additional, Negrier, Sylvie, additional, Szczylik, Cezary, additional, Pili, Roberto, additional, Bjarnason, Georg A., additional, Garcia-del-Muro, Xavier, additional, Sosman, Jeffrey A., additional, Solska, Ewa, additional, Wilding, George, additional, Thompson, John A., additional, Kim, Sindy T., additional, Chen, Isan, additional, Huang, Xin, additional, and Figlin, Robert A., additional

Published
2023
Full Text
View/download PDF

33. Supplementary Methods and Figures and Tables from The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma

Author

Choueiri, Toni K., primary, Fay, André P., primary, Gagnon, Robert, primary, Lin, Ying, primary, Bahamon, Brittany, primary, Brown, Victoria, primary, Rosenberg, Jonathan E., primary, Hutson, Thomas E., primary, Baker-Neblett, Katherine L., primary, Carpenter, Christopher, primary, Liu, Yuan, primary, Pandite, Lini, primary, and Signoretti, Sabina, primary

Published
2023
Full Text
View/download PDF

35. Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II).

Author

Grivas, Petros, primary, Barata, Pedro C., additional, Moon, Helen, additional, Hutson, Thomas E., additional, Gupta, Shilpa, additional, Sternberg, Cora N., additional, Dave, Vaidehi, additional, Downey, Chad, additional, Shillington, Alicia C., additional, Devgan, Geeta, additional, Kirker, Melissa, additional, Thakkar, Sheena, additional, Katzenstein, Howard M., additional, Bhanegaonkar, Abhijeet, additional, Liu, Frank, additional, Brown, Jason, additional, and Sonpavde, Guru P., additional

Published
2023
Full Text
View/download PDF

47. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

Author

Grünwald, Viktor, Powles, Thomas, Masatoshi Eto, Kopyltsov, Evgeny, Sun Young Rha, Porta, Camillo, Motzer, Robert, Hutson, Thomas E., José Méndez-Vidal, María, Sung-Hoo Hong, Winquist, Eric, Goh, Jeffrey C., Maroto, Pablo, Buchler, Tomas, Toshio Takagi, Burgents, Joseph E., Perini, Rodolfo, Cixin He, Okpara, Chinyere E., and McKenzie, Jodi

Subjects
SUNITINIB, BONE metastasis, THERAPEUTICS, TREATMENT effectiveness, PROGRESSION-free survival
Abstract

Introduction: The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence and/or site of baseline metastases, prior nephrectomy, and sarcomatoid features have been associated with disease and treatment success. This subsequent analysis explores outcomes in patients with or without specific prognostic features. Methods: In CLEAR, patients with clear cell RCC were randomly assigned (1:1:1) to receive either lenvatinib (20 mg/day) plus pembrolizumab (200 mg every 3 weeks), lenvatinib (18 mg/day) plus everolimus (5 mg/day), or sunitinib alone (50 mg/day, 4 weeks on, 2 weeks off). In this report, progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were all assessed in the lenvatinib-plus-pembrolizumab and the sunitinib arms, based on baseline features: lung metastases, bone metastases, liver metastases, prior nephrectomy, and sarcomatoid histology. Results: In all the assessed subgroups, median PFS was longer with lenvatinib-plus-pembrolizumab than with sunitinib treatment, notably among patients with baseline bone metastases (HR 0.33, 95% CI 0.21–0.52) and patients with sarcomatoid features (HR 0.39, 95% CI 0.18–0.84). Median OS favored lenvatinib plus pembrolizumab over sunitinib irrespective of metastatic lesions at baseline, prior nephrectomy, and sarcomatoid features. Of interest, among patients with baseline bone metastases the HR for survival was 0.50 (95% CI 0.30–0.83) and among patients with sarcomatoid features the HR for survival was 0.91 (95% CI 0.32–2.58); though for many groups, median OS was not reached. ORR also favored lenvatinib plus pembrolizumab over sunitinib across all subgroups; similarly, complete responses also followed this pattern. Conclusion: Efficacy outcomes improved following treatment with lenvatinib-plus-pembrolizumab versus sunitinib in patients with RCC—irrespective of the presence or absence of baseline lung metastases, baseline bone metastases, baseline liver metastases, prior nephrectomy, or sarcomatoid features. These findings corroborate those of the primary CLEAR study analysis in the overall population and support lenvatinib plus pembrolizumab as a standard of care in 1L treatment for patients with advanced RCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Carcinoma of the Unknown Primary

Author

Hutson, Thomas E., Bukowski, Ronald M., Markman, Maurie, editor, McLain, Robert F., editor, Lewandrowski, Kai-Uwe, editor, Bukowski, Ronald M., editor, Macklis, Roger, editor, and Benzel, Edward C., editor

Published
2006
Full Text
View/download PDF

49. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

Author

George, Daniel J, primary, Spigel, David R, additional, Gordan, Lucio N, additional, Kochuparambil, Samith T, additional, Molina, Ana M, additional, Yorio, Jeff, additional, Rezazadeh Kalebasty, Arash, additional, McKean, Heidi, additional, Tchekmedyian, Nishan, additional, Tykodi, Scott S, additional, Zhang, Joshua, additional, Askelson, Margarita, additional, Johansen, Jennifer L, additional, and Hutson, Thomas E, additional

Published
2022
Full Text
View/download PDF

50. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Powles, Thomas, primary, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Thomas, additional, Symeonides, Stefan N, additional, Hajek, Jaroslav, additional, Gurney, Howard, additional, Chang, Yen-Hwa, additional, Lee, Jae Lyun, additional, Sarwar, Naveed, additional, Thiery-Vuillemin, Antoine, additional, Gross-Goupil, Marine, additional, Mahave, Mauricio, additional, Haas, Naomi B, additional, Sawrycki, Piotr, additional, Burgents, Joseph E, additional, Xu, Lei, additional, Imai, Kentaro, additional, Quinn, David I, additional, Choueiri, Toni K, additional, Choueiri, Toni, additional, Ferguson, Thomas R., additional, Lin, Tzu-Ping, additional, Symeonides, Stefan N., additional, Haas, Naomi B., additional, Gurney, Howard P., additional, Chevreau, Christine, additional, Burke, John M., additional, Doshi, Gurjyot, additional, Melichar, Bohuslav, additional, Topart, Delphine, additional, Oudard, Stephane, additional, Kopyltsov, Evgeniy, additional, Hammers, Hans-Joerg, additional, Quinn, David I., additional, Alva, Ajjai, additional, Menezes, Juliana de Janoski, additional, Silva, Adriano Goncalves e, additional, Winquist, Eric W., additional, Hamzaj, Alketa, additional, Procopio, Giuseppe, additional, Karaszewska, Boguslawa, additional, Nowakowska-Zajdel, Ewa M., additional, Alekseev, Boris Y., additional, Gafanov, Rustem A., additional, Izmailov, Adel, additional, Semenov, Andrey, additional, Afanasyev, Sergey G., additional, Lipatov, Oleg N., additional, Powles, Thomas B., additional, Srinivas, Sandy, additional, McDermott, David, additional, Kochuparambil, Samith T., additional, Davis, Ian D., additional, Peltola, Katriina, additional, Sabbatini, Roberto, additional, Chung, Jinsoo, additional, Shkolnik, Michail I., additional, Matveev, Vsevolod B., additional, Gajate Borau, Pablo, additional, McCune, Steven, additional, Hutson, Thomas E., additional, Dri, Alejandro, additional, Sales, Silvio Correia, additional, Yeung, Carrie, additional, Alcala Castro, Carmen Marcela, additional, Bostrom, Peter, additional, Laguerre, Brigitte, additional, Buttigliero, Consuelo, additional, de Giorgi, Ugo, additional, Fomin, Eugeniy A., additional, Zakharia, Yousef, additional, Hwang, Clara, additional, Singer, Eric A., additional, Yorio, Jeffrey T., additional, Waterhouse, David, additional, Kowalyszyn, Ruben Dario, additional, Alfie, Margarita Sonia, additional, Yanez Ruiz, Eduardo, additional, Buchler, Tomas, additional, Kankaanranta, Krista, additional, Ferretti, Gianluigi, additional, Kimura, Go, additional, Nishimura, Kazuo, additional, Masumori, Naoya, additional, Tamada, Satoshi, additional, Kato, Haruaki, additional, Kitamura, Hiroshi, additional, Danielewicz, Iwona, additional, Wojcik-Tomaszewska, Joanna, additional, Sala Gonzalez, Nuria, additional, Chiu, Kun-Yuan, additional, Atkins, Michael B., additional, Heath, Elisabeth, additional, Rojas-Uribe, Gustavo Adolfo, additional, Gonzalez Fernandez, Manuel Enrique, additional, Feyerabend, Susan, additional, Pignata, Sandro, additional, Numakura, Kazuyuki, additional, Cybulska Stopa, Bozena, additional, Zukov, Ruslan, additional, Climent Duran, Miguel Angel, additional, Maroto Rey, Pablo Jose, additional, Montesa Pino, Alvaro, additional, Chang, Chao-Hsiang, additional, Vengalil, Salil, additional, Waddell, Tom S., additional, Cobb, Patrick W., additional, Hauke, Ralph, additional, Anderson, Daniel M., additional, Sarantopoulos, John, additional, Gourdin, Theodore, additional, Zhang, Tian, additional, Jayram, Gautam, additional, Fein, Luis Enrique, additional, Harris, Carole, additional, Beato, Patricia Medeiros Milhomem, additional, Flores, Francisco, additional, Estay, Angela, additional, Rubiano, Juan Andres, additional, Bedke, Jens, additional, Hauser, Stefan, additional, Neisius, Andreas, additional, Busch, Jonas, additional, Anai, Satoshi, additional, Tsunemori, Hiroyuki, additional, Sawka, Dariusz, additional, Sikora-Kupis, Bozena, additional, Arranz, Jose Angel, additional, Delgado, Ignacio, additional, Chen, Chung-Hsin, additional, Gunderson, Elizabeth, additional, Tykodi, Scott, additional, Koletsky, Alan, additional, Chen, Kevin, additional, Agrawal, Manish, additional, Kaen, Diego Lucas, additional, Sade, Juan Pablo, additional, Tatangelo, Marcelo Daniel, additional, Parnis, Francis, additional, Barbosa, Fernando Maciel, additional, Faucher, Genevieve, additional, Iqbal, Nayyer, additional, Marceau, Daniele, additional, Paradis, Jean-Benoit, additional, Hanna, Nawar, additional, Acevedo, Alejandro, additional, Ibanez, Carolina, additional, Villanueva, Luis, additional, Galaz, Pedro Pablo, additional, Durango, Isabel Cristina, additional, Manneh, Ray, additional, Kral, Zdenek -, additional, Holeckova, Petra, additional, Hakkarainen, Heikki, additional, Ronkainen, Hanna, additional, Abadie-Lacourtoisie, Sophie, additional, Tartas, Sophie, additional, Goebell, Peter J., additional, Grimm, Marc-Oliver, additional, Hoefner, Thomas, additional, Wirth, Manfred, additional, Panic, Andrej, additional, Schultze-Seemann, Wolfgang, additional, Yokomizo, Akira, additional, Mizuno, Ryuichi, additional, Uemura, Hirotsugu, additional, Eto, Masatoshi, additional, Tsujihata, Masao, additional, Matsukawa, Yoshihisa, additional, Murakami, Yoji, additional, Kim, Miso, additional, Hamberg, Paul, additional, Marczewska-Skrodzka, Malgorzata, additional, Szczylik, Cezary, additional, Humphreys, Alison C., additional, Jiang, Peter, additional, Kumar, Birendra, additional, Lu, Gary, additional, Desai, Arpita, additional, Karam, Jose Antonio, additional, Keogh, George, additional, Fleming, Mark, additional, Zarba, Juan Jose, additional, Leiva, Viviana E., additional, Mendez, Guillermo Ariel, additional, Harris, Samuel J., additional, Brown, Stephen J., additional, Antonio Junior, Joao Neif, additional, Costamilan, Rita de Cassia, additional, Rocha, Roberto Odebrecht, additional, Muniz, David, additional, Brust, Leandro, additional, Lalani, Aly-Khan, additional, Graham, Jeffrey, additional, Levesque, Michael, additional, Orlandi, Francisco, additional, Kotasek, Rostislav, additional, Deville, Jean L., additional, Borchiellini, Delphine, additional, Merseburger, Axel, additional, Rink, Michael, additional, Roos, Frederik, additional, McDermott, Ray, additional, Oyama, Masafumi, additional, Yamamoto, Yoshiaki, additional, Tomita, Yoshihiko, additional, Miura, Yuji, additional, Ioritani, Naomasa, additional, Westgeest, Hans, additional, Kubiatowski, Tomasz, additional, Bal, Wieslaw, additional, Girones Sarrio, Regina, additional, Rowe, Julie, additional, Prow, Debra M., additional, Senecal, Francis, additional, Hashemi-Sadraei, Neda, additional, Cole, Scott W., additional, Kendall, Stephan D., additional, Richards, Donald A., additional, Schnadig, Ian D., additional, and Gupta, Mukul, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results